Lynn Anson-Cartwright is the Clinical Research Co-Ordinator, Testicular Cancer Program in the department of Radiation Oncology at The Princess Margaret. She co-ordinates clinical trials involving men with testicular germ cell tumours, as well as research activities for the The Princess Margaret Oncology Program - Testis Group. Over the past 6 years, Lynn has been involved in clinical research on men diagnosed with Germ Cell Tumours treated at the The Princess Margaret over the past 30 years.
Dr. Bayley is a physician in the department of radiation oncology at UHN and an assistant professor in the department of radiation oncology at University of Toronto. He specializes in head and neck and genitourinary cancers. His academic and clinical interests include genitourinary oncology, gastrointestinal oncology, image co-registration for radiation therapy planning and assessment of acute and late toxicity after radiation therapy.
Dr. Bristow is a Clinician-Scientist and Professor within the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto. He is a Senior Scientist at the Ontario Cancer Institute and a Radiation Oncologist in genitourinary cancers at The Princess Margaret (University Health Network). Dr Bristow is Head of the The Princess Margaret-Campbell Family Research Institute Prostate Cancer Research Program. He co-leads the Terry Fox Foundation Project Program Hypoxia Team Grant at The Princess Margaret. He is Lead for the Canadian BRCA1/2 Prostate Cancer Network and the Canadian Prostate Cancer Genome Sequencing Project (CPC-GENE).
Dr Bristow’s prostate cancer research program involves the role of DNA damage response and DNA repair during experimental radiotherapy and chemotherapy, the role of tumour oxygen and hypoxia in prostate cancer progression and treatment response and high-throughput genomic and proteomic signatures that predict radiotherapy and chemotherapy treatment response. As an educator, Dr Bristow has directly supervised more than 50 basic science undergraduates, graduate and post-doctoral trainees and 25 clinical residents or post-graduate fellows. He was awarded the Post-Graduate Medical Education Excellence Award in Teaching in the Faculty of Medicine, University of Toronto. He has over 200 published papers, abstracts and book chapters. He was made a Canadian Cancer Society Career Research Scientist in 2004 and is twice an Awardee of the Canadian Foundation of Innovation (CFI).
Dr. Catton is a Radiation Oncologist in the Department of Radiation Oncology, The Princess Margaret (University Health Network), and the Director of the Fellowship Program, Department of Radiation Oncology at the University of Toronto. He is currently a professor at the University of Toronto, and an Executive Member, GU disease Oriented Group, NCIC-CTG.
Dr. Catton provides Radiation Oncology consultative and treatment services and participates in the clinical and translational research program for prostate cancer at The Princess Margaret. As the leader of the administrative program for the GU site, Dr. Catton integrates the clinical and research program of the Prostate Centre into the Genitourinary Oncology program as a whole.
Dr. Catton's primary research goal is to develop high-precision radiation techniques for the treatment of GU malignancies. His current research project is an international phase III trial of immediate vs early salvage post-operative radiotherapy for limited-stage prostate cancer, with long term, short term, or no androgen ablation.
Dr. Chung is a radiation oncologist and researcher who specializes in radiation treatment of genitourinary cancer. He has a special interest in bladder and testicular cancer and is also part of the prostate brachytherapy team. His research focuses on image guided radiotherapy, and MR guided brachytherapy techniques.
His work focuses on improving the delivery of radiation treatment for patients with genitourinary malignancy. This includes promotion of best practices and reduction of treatment related complications in order to provide optimal outcomes. He has an interest in Brachytherapy for prostate cancer, particularly in locally recurrent cancer after previous prostate external beam radiation.
Dr. Gospodarowicz is the Medical Director of the Cancer Program at The Princess Margaret and University Health Network and the Regional Vice President of Cancer Care Ontario. She is also the Professor and Chair of the Department of Radiation Oncology at the University of Toronto and Chief of the Radiation Medicine Program at The Princess Margaret. Her academic and clinical interests include bladder cancer, seminoma, lymphoma, Hodgkin’s disease, prostate cancer, cancer staging and prognostic factors and clinical trials.
Dr. Parameswaran is an Assistant Professor in Radiation Oncology at The Princess Margaret, UHN. Trained in Radiation Oncology in India, he completed clinical fellowships in prostate brachytherapy as well as high precision radiotherapy techniques. At the Prostate Centre Dr. Parameswaran is a radiation oncologist with a main focus on brachytherapy for prostate and penile cancer and is involved in RTOG brachytherapy trials in prostate cancer.
Dr. Parameswaran's research focuses on improving cancer control with organ preservation and minimal toxicity for patients through precise radiation delivery. To read his research, click here.
Dr. Cynthia Ménard joined The Pencer Center at The Princess Margaret in September 2004. She received her M.D. degree from the University of Calgary, in 1996 and completed her residency in radiation oncology at the University of Alberta, Edmonton, in 2001. Until 2003 she was an ASTRO Translational Research Fellow in the Radiation Oncology Branch of the National Cancer Institute (NCI) in Bethesda, Maryland, USA. She then held a Staff Clinician appointment at NCI and headed the Radiation Oncology Molecular Imaging Section where she pursued research in the development, validation, and clinical application of novel magnetic resonance imaging (MRI) techniques to cancer radiotherapy. She is now appointed as a Clinician Scientist and Assistant Professor in the Department of Radiation Oncology. She chairs the MRI Simulator Research Group, and actively pursues research in image-guidance for stereotactic radiotherapy and external beam radiotherapy for brain tumors.
Dr. Milosevic is a Professor in the Department of Radiation Oncology at the University of Toronto, a Radiation Oncologist at The Princess Margaret and the past-president of the Canadian Association of Radiation Oncology. His primary clinical interest is in the management of gynecologic cancer, and has been the Radiation Medicine Program Gynecologic Oncology Site Leader since 1997. His research revolves around the use of image-guided, adaptive, intensity modulated radiotherapy ((IMRT) to treat cervical cancer. His other main research interest is the development of biology-based approaches to improving the effectiveness of radiotherapy, particularly in relation to tumour hypoxia and altered metabolism. He is a co-founder of the STTARR Research Program and the STTARR Innovation Centre in Toronto, which integrate molecular, cellular, animal and patient imaging with precision radiation research in a manner conducive to the rapid translation of novel treatment strategies from the laboratory to the clinic.
Dr. Warde has been a radiation oncologist at The Princess Margaret since 1987, where his academic practice focused on genitourinary cancer. Dr. Warde has also worked as an Associate Director and Deputy Head of the Radiation Medicine Program at The Princess Margaret since 1999. Here, he led a comprehensive effort to improve processes within the program and advanced new roles for medical radiation therapists. His clinical and academic interests include prostate cancer, seminoma, bladder cancer, head and neck cancer and clinical trials.